Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

SHA:688076 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,840	1,623	1,033	648.03	641.71	564.99
Other Revenue	1.66	1.99	0.82	3.26	2.16	1.89
Revenue	1,842	1,625	1,034	651.29	643.87	566.87
Revenue Growth (YoY)	25.77%	57.21%	58.69%	1.15%	13.58%	52.58%
Cost of Revenue	641.31	575.05	444.27	307.94	306.3	249.55
Gross Profit	1,200	1,050	589.28	343.36	337.57	317.32
Selling, General & Admin	398.27	339.13	268.23	186.98	150.49	120
Research & Development	236.36	227.45	124.89	69.47	63.09	60.53
Other Operating Expenses	5.82	1.7	0.02	9.25	5.24	3.65
Operating Expenses	652.69	588.89	398.25	271.58	220.47	185.87
Operating Income	547.58	460.86	191.04	71.78	117.1	131.45
Interest Expense	-47.8	-34.75	-16.09	-9.26	-6.12	-11.63
Interest & Investment Income	11.65	9.05	9.11	28.54	8.38	7.16
Currency Exchange Gain (Loss)	7.02	8.68	-1.38	1.03	-1.58	-7.73
Other Non Operating Income (Expenses)	-1.38	-0.58	-0.47	-0.3	-0	-1.12
EBT Excluding Unusual Items	517.07	443.26	182.22	91.79	117.78	118.14
Impairment of Goodwill	-	-	-	-	-1.28	-
Gain (Loss) on Sale of Investments	-0.25	-2.79	0.26	-1.96	0.13	-
Gain (Loss) on Sale of Assets	-7.71	-9.2	-15.06	18.44	-0.97	-4.12
Other Unusual Items	12.2	7.24	5.71	14.9	10.07	32.55
Pretax Income	521.31	438.5	173.13	123.16	125.73	146.56
Income Tax Expense	50.89	38.69	7.67	0.39	16.92	26.53
Earnings From Continuing Operations	470.41	399.82	165.45	122.77	108.81	120.03
Minority Interest in Earnings	16.86	4.57	-2.52	6.34	6.58	3.41
Net Income	487.28	404.39	162.94	129.11	115.39	123.44
Net Income to Common	487.28	404.39	162.94	129.11	115.39	123.44
Net Income Growth	39.92%	148.19%	26.20%	11.89%	-6.52%	153.94%
Shares Outstanding (Basic)	308	301	300	296	269	224
Shares Outstanding (Diluted)	309	308	300	296	269	224
Shares Change (YoY)	-0.19%	2.52%	1.28%	10.06%	19.95%	-1.06%
EPS (Basic)	1.58	1.34	0.54	0.44	0.43	0.55
EPS (Diluted)	1.58	1.31	0.54	0.44	0.43	0.55
EPS Growth	40.19%	142.09%	24.60%	1.66%	-22.07%	156.65%
Free Cash Flow	-930.99	-690.01	-310.43	-409.07	-52.61	30.1
Free Cash Flow Per Share	-3.02	-2.24	-1.03	-1.38	-0.20	0.13
Dividend Per Share	0.572	0.643	0.286	0.143	0.107	-
Dividend Growth	60.04%	125.03%	99.93%	33.43%	-	-
Gross Margin	65.18%	64.61%	57.02%	52.72%	52.43%	55.98%
Operating Margin	29.73%	28.36%	18.48%	11.02%	18.19%	23.19%
Profit Margin	26.46%	24.89%	15.77%	19.82%	17.92%	21.78%
Free Cash Flow Margin	-50.55%	-42.47%	-30.04%	-62.81%	-8.17%	5.31%
EBITDA	788.02	662.75	322.81	170.52	198.73	202.16
EBITDA Margin	42.79%	40.79%	31.23%	26.18%	30.87%	35.66%
D&A For EBITDA	240.45	201.88	131.77	98.75	81.63	70.71
EBIT	547.58	460.86	191.04	71.78	117.1	131.45
EBIT Margin	29.73%	28.36%	18.48%	11.02%	18.19%	23.19%
Effective Tax Rate	9.76%	8.82%	4.43%	0.32%	13.46%	18.10%
Revenue as Reported	1,842	1,625	1,034	651.29	643.87	566.87

Source: S&P Global Market Intelligence. Standard template. Financial Sources.